PE/VC  RA Capital Management

https://www.racap.com/





     Office Locations:

200 Berkeley St., 18th Floor
Boston, MA 02116
Phone: 617-778-2500

 

Stages:

  • Early
  • Expansion
  • Growth
  • Middle Market


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. At RA Capital's core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides RA Capital's investment team and portfolio companies (see Beyond Capital) with strategic intelligence, market research, and other resources. The team's understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability. Additionally, RA Capital offers an Executive-in-Residence (EIR) program for experienced professionals seeking thought partners and a platform from which to survey diverse competitive landscapes in search of worthy projects. The firm might invest a small amount in a very small company, maybe even under $1M in a seed round, or a larger amount in a large company that they think has a lot of upside (they have invested as much as $75M in a single round). But are unlikely to invest a small amount in a large company (e.g. $5M in a $500M to own 1%) unless it’s just the first step towards establishing greater ownership.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Andrew Levin MD, PhD Managing Director
    Derek DiRocco PhD Principal
    Josh Resnick MD Managing Director
    Lorena Chen CPA Fund Controller
    Matthew Hammond PhD Principal

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/25/2021


      Cedilla Therapeutics


      MA


      $82,600,000


      Series B


      09/29/2021


      Expansion Therapeutics


      CA


      $80,000,000


      Series B


      09/08/2021


      HilleVax


      MA


      $135,000,000


      Crossover Financing


      08/10/2021


      Sydnexis


      CA


      $45,000,000


      Series B


      07/29/2021


      Exo Imaging


      CA


      $220,000,000


      Series C


      07/15/2021


      Nimbus Therapeutics


      MA


      $105,000,000


      


      05/24/2021


      Eliem Therapeutics


      WA


      $60,000,000


      Series B


      04/28/2021


      Boundless Bio


      CA


      $105,000,000


      Series B


      04/20/2021


      Janux Therapeutics


      CA


      $125,000,000


      Series B


      04/20/2021


      Adagio Therapeutics


      MA


      $336,000,000


      Series C


      04/13/2021


      Antios Therapeutics


      GA


      $96,000,000


      Series B


      04/07/2021


      Icosavax


      WA


      $100,000,000


      Series B


      03/31/2021


      Scribe Therapeutics


      CA


      $100,000,000


      Series B


      03/30/2021


      Pyxis Oncology


      MA


      $152,000,000


      Series B


      03/03/2021


      Janux Therapeutics


      CA


      $56,000,000


      Series A


      03/02/2021


      Artiva Biotherapeutics


      CA


      $120,000,000


      Series B


      03/02/2021


      Tenaya Therapeutics


      CA


      $106,000,000


      Series C


      02/25/2021


      Xilio Therapeutics


      MA


      $95,000,000


      Series C


      02/24/2021


      Vividion Therapeutics


      CA


      $135,000,000


      Series C


      02/11/2021


      Cyteir Therapeutics


      MA


      $80,000,000


      Series C


      02/11/2021


      Day One Biopharmaceuticals


      CA


      $130,000,000


      Series B


      01/25/2021


      TScan Therapeutics


      MA


      $100,000,000


      Series C


      01/19/2021


      Verve Therapeutics


      MA


      $94,000,000


      Series B


      01/08/2021


      DiCE Molecules


      CA


      $80,000,000


      Series C


      12/14/2020


      Locana


      CA


      $100,000,000


      Series B


     

    Portfolio companies include:


      89Bio
        web link


      AavantiBio
        web link


      Adagio Therapeutics
        web link


      Aerovate Therapeutics
        web link


      Akouos
        web link


      Antios Therapeutics
        web link


      Artiva Biotherapeutics
        web link


      Be Biopharma
        web link


      Black Diamond Therapeutics
        web link


      Boundless Bio
        web link


      Braeburn Pharmaceuticals
        web link


      Cedilla Therapeutics
        web link


      Cerebral Therapeutics
        web link


      Cyteir Therapeutics
        web link


      Day One Biopharmaceuticals
        web link


      DiCE Molecules
        web link


      Eliem Therapeutics
        web link


      Exo Imaging
        web link


      Expansion Therapeutics
        web link


      Forma Therapeutics
        web link


      Freenome
        web link


      GentiBio
        web link


      HilleVax
        web link


      Icosavax
        web link


      Inozyme Pharma
        web link


      iTeos Therapeutics
        web link


      Ivantis
        web link


      Janux Therapeutics
        web link


      Kinnate Biopharma
        web link


      Legend Biotech
        web link


      Locana
        web link


      Lyra Therapeutics
        web link


      Medeor Therapeutics
        web link


      Nimbus Therapeutics
        web link


      Olema Oncology
        web link


      Orchard Therapeutics
        web link


      PMV Pharma
        web link


      Pyxis Oncology
        web link


      Quench Bio
        web link


      Satsuma
        web link


      Scribe Therapeutics
        web link


      Silverback Therapeutics
        web link


      Spero Therapeutics
        web link


      Stoke Therapeutics
        web link


      SutroVax
        web link


      Sydnexis
        web link


      Synthego
        web link


      Synthorx
        web link


      Tenaya Therapeutics
        web link


      TeraPore Technologies
        web link


      TScan Therapeutics
        web link


      Verve Therapeutics
        web link


      ViaCyte


      Vividion Therapeutics
        web link


      Vor Biopharma
        web link


      Xilio Therapeutics
        web link


     

    Recent News: